E-LIB Suche - Ergebnisse für: Scher, H.I.

1

Development and validation of circulating tumour cell enume..:

Scher, H.I. ; Armstrong, A.J. ; Schonhoft, J.D....
European Journal of Cancer. 150 (2021) - p. 83-94 , 2021

Link: https://doi.org/10.1016/..

2

Circulating tumour cell increase as a biomarker of disease ..:

Lorente, D. ; Olmos, D. ; Mateo, J....
Annals of Oncology. 29 (2018) 7 - p. 1554-1560 , 2018

Link: https://doi.org/10.1093/..

3

Periprostatic adipose inflammation is associated with high-..:

Gucalp, A ; Iyengar, N M ; Zhou, X K...
Prostate Cancer and Prostatic Diseases. 20 (2017) 4 - p. 418-423 , 2017

Link: https://doi.org/10.1038/..

4

The TRITON clinical trial programme: evaluation of the PARP..:

Rodriguez-Vida, A. ; Arranz Arija, J.A. ; Daugaard, G....
European Urology Supplements. 16 (2017) 10 - p. e2689-e2690 , 2017

Link: https://doi.org/10.1016/..

5

A prognostic index model for predicting overall survival in..:

Chi, K.N. ; Kheoh, T. ; Ryan, C.J....
Annals of Oncology. 27 (2016) 3 - p. 454-460 , 2016

Link: https://doi.org/10.1093/..

6

564 Assessment of corticosteroid (CS)-associated adverse ev..:

Miller, K. ; Chi, K. ; De Bono, J.S....
European Urology Supplements. 14 (2015) 2 - p. e564 , 2015

Link: https://doi.org/10.1016/..

7

Enzalutamide: Development from bench to bedside:

Bambury, R.M. ; Scher, H.I.
Urologic Oncology: Seminars and Original Investigations. 33 (2015) 6 - p. 280-288 , 2015

Link: https://doi.org/10.1016/..

8

444 Presence of AR-V7 splice variant or AR C terminal loss ..:

Scher, H.I. ; Kelvin, J. ; Lu, D....
European Journal of Cancer. 51 (2015) - p. S93 , 2015

Link: https://doi.org/10.1016/..

9

861 Impact of prior endocrine therapy on radiographic progr..:

Schrijvers, D. ; Kheoh, T. ; Yu, M.K....
European Urology Supplements. 13 (2014) 1 - p. e861-e861a , 2014

Link: https://doi.org/10.1016/..

10

Androgen dynamics and serum PSA in patients treated with ab..:

Ryan, C J ; Peng, W ; Kheoh, T...
Prostate Cancer and Prostatic Diseases. 17 (2014) 2 - p. 192-198 , 2014

Link: https://doi.org/10.1038/..

11

864 Does Gleason score at initial diagnosis predict efficac..:

Stöckle, M. ; Flaig, T. ; Ohlmann, C.H....
European Urology Supplements. 13 (2014) 1 - p. e864-e864a , 2014

Link: https://doi.org/10.1016/..

12

105 Exploratory analysis of the visceral disease patient su..:

Suttmann, H. ; Mulders, P.F.A. ; Molina, A....
European Urology Supplements. 12 (2013) 1 - p. e105-e106 , 2013

Link: https://doi.org/10.1016/..

13

97 Updated interim analysis (IA): Results of randomized pha..:

Van Poppel, H. ; Rathkopf, D. ; Smith, M.R....
European Urology Supplements. 12 (2013) 1 - p. e97-e98 , 2013

Link: https://doi.org/10.1016/..

14

P109 Efficacy outcomes by baseline prostate-specific antige..:

Loriot, Y. ; Saad, F. ; De Bono, J.S....
European Urology Supplements. 12 (2013) 6 - p. 173 , 2013

Link: https://doi.org/10.1016/..

15

P106 Results from a Phase I study of enzalutamide in combin..:

Fleming, M. ; Rathkopf, D. ; Gibbons, J....
European Urology Supplements. 12 (2013) 6 - p. 171-172 , 2013

Link: https://doi.org/10.1016/..